Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rxo (RXO) Revenue (2021 - 2025)

Rxo (RXO) has disclosed Revenue for 5 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue fell 11.88% year-over-year to $1.5 billion, compared with a TTM value of $5.7 billion through Dec 2025, up 26.2%, and an annual FY2025 reading of $5.7 billion, up 26.2% over the prior year.
  • Revenue was $1.5 billion for Q4 2025 at Rxo, up from $1.4 billion in the prior quarter.
  • Across five years, Revenue topped out at $1.7 billion in Q4 2024 and bottomed at $913.0 million in Q1 2024.
  • Average Revenue over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2022.
  • The sharpest move saw Revenue dropped 23.02% in 2023, then surged 70.45% in 2024.
  • Year by year, Revenue stood at $1.3 billion in 2021, then fell by 15.6% to $1.1 billion in 2022, then fell by 12.68% to $978.0 million in 2023, then soared by 70.45% to $1.7 billion in 2024, then dropped by 11.88% to $1.5 billion in 2025.
  • Business Quant data shows Revenue for RXO at $1.5 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.4 billion in Q2 2025.